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Background: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and infiltration
of IgG4+ plasma cells into multiple organs. It is not known whether serum IgG4 is autoreactive in IgG4-RD.
Methods: We measured anti-nuclear antibody (ANA) in 19 IgG4-RD cases, determined IgG subclasses of the ANA, and
compared them with those of other systemic autoimmune diseases (systemic lupus erythematosus, Sjögren’s syndrome,
systemic sclerosis, and polymyositis), using subclass-based ANA test (indirect immunofluorescence).
Results: 58 % of IgG4-RD cases were ANA-positive (cut-off: 1:40). Whereas their subclass of ANA was predominantly
IgG2, we observed no IgG4-type ANA. In systemic autoimmune diseases, subclasses of ANA were mostly IgG1, 2, or 3,
but IgG4-type ANA was very rarely detected. We also found several patients in whose serum ANA patterns differed
among IgG subclasses, probably due to the difference of corresponding autoantigens.
Conclusions: Although IgG4 is highly elevated in sera of IgG4-RD patients, their ANA do not include IgG4 subclass.
These results offer new insight into the role of IgG4 and the pathogenesis of IgG4-RD, implying that each IgG subclass
tends to cover its own spectrum of antigens, and IgG4 is not preferentially used to make ANA.
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Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a
multi-organ disorder characterized by elevated serum
IgG4, organ infiltration by IgG4+ plasma cells, hypergam-
maglobulinemia, and tissue sclerosis [1–4]. Many organs,
such as lacrimal gland, salivary gland, eye orbit, lymph
node, thyroid gland, lung, pancreas, kidney, retroperito-
neum, and prostate can be affected by IgG4-RD. The role
of IgG4 in IgG4-RD is not sufficiently understood. Some
view IgG4-RD as an allergic disease, because IgG4-RD is
often complicated in allergic diseases and serum IgE levels
are often high in IgG4-RD. Others see IgG4-RD as an
autoimmune disease, because anti-lactoferrin [5] and car-
bonic anhydrase II [6] antibodies are detected in some of
IgG4-related autoimmune pancreatitis cases, and because
IgG4-RD cases usually show good responses to gluco-
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unless otherwise stated.At this point, there is no consensus that IgG4-related
disease is an autoimmune disorder. To examine whether
IgG4 in IgG4-RD is autoreactive, we determined IgG
subclasses of serum anti-nuclear antibody (ANA) in
IgG4-RD patients and compared them with those in pa-
tients with systemic autoimmune diseases such as sys-
temic lupus erythematosus (SLE), Sjögren’s syndrome
(SS), systemic sclerosis (SSc), and polymyositis (PM).
Using a subclass-based ANA test that was derived from
indirect immunofluorescence (IIF), we investigated how
frequently IgG4 was included in ANA in IgG4-RD. We
also examined how frequently each IgG subclass was in-
cluded in ANA in systemic autoimmune diseases.
Methods
Patients
Patients were recruited from Department of Rheumatology
and Clinical Immunology, Kyoto University Hospital,
Kyoto, Japan. The patients were definitely diagnosed by
the 2011 Comprehensive Diagnostic Criteria proposed
by the IgG4-RD research team of Ministry of Health,
Labour and Welfare (MHLW), Japan [4]: (1) diffuse or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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elevated serum IgG4 levels ≥135 mg/dL, (3a) fibrosis
with remarkable infiltration of lymphocytes and plasma
cells, and (3b) IgG4+/IgG+ plasma cell ratio > 0.4, and >
10 IgG4+ plasma cells in a high-power field. No IgG4-
RD patients were considered having SS, Castleman’s
disease, sarcoidosis, granulomatosis with polyangiitis,
or malignant lymphoma. As ANA-positive disease con-
trols, we enrolled 8 SLE patients diagnosed by the 1997
American College of Rheumatology revised criteria [7],
8 SS patients diagnosed by the 1999 revised criteria of
MHLW, Japan [8], 4 SSc patients diagnosed by the
1980 American College of Rheumatology criteria [9],
and 7 PM patients diagnosed by Bohan and Peter’s cri-
teria [10]. All participants provided informed consent
in accordance with the Declaration of Helsinki. This
study was approved by the Medical Ethics Committee
of Graduate School of Medicine and Faculty of Medicine,
Kyoto University.
Detection of subclass-specific ANA
We performed subclass-based ANA tests based on the
Fluoro-HepANA™ test (Medical & Biological Laborator-
ies, Nagoya, Japan). Briefly, HEp-2 cell-coated slides
were incubated with sera, washed with PBS, incubated
with FITC-labeled second antibodies, and observed withTable 1 Clinical, serological, and histopathological features of IgG4-R
Case Age IgG4a IgGa ANA Specific Abs RFb Clinical man
1 73 2890 3668 40 (Homo + Spe) <6 Mikulicz’s di
2 76 2210 3632 40 (Spe) <6 Mikulicz’s di
3c 79 1460 3669 160 (Homo + Spe) Anti-SS-A+ <6 Küttner’s tum
4 66 1090 2301 40 (Homo + Spe) 30.3 AIP, IN, Rena
5c 73 592 3321 320 (Homo + Spe) <6 Sialadenitis,
6 74 389 2184 <40 <6 Retroorbital
7 52 383 1748 <40 <6 Küttner’s tum
8 70 724 1729 <40 <6 Küttner’s tum
9 46 675 1617 80 (Homo + Spe) 26.8 Mikulicz’s di
10 37 533 1741 <40 <6 Mikulicz’s di
11 76 458 1527 <40 <6 AIP, RPF
12 62 315 1809 40 (Spe) Anti-SS-A+ <6 AIP, RPF
13 79 1960 2953 40 (Homo + Spe) 65 Orbital tumo
14c 62 1460 2177 40 (Spe) 23.3 Sialadenitis,
15 65 1050 1811 <40 19.8 Mikulicz’s di
16 25 1210 2181 <40 <6 Mikulicz’s di
17 55 1510 3116 <40 72.2 Orbital tumo
18 61 491 1466 80 (Spe + Granular) <6 Sialadenitis
19 78 1470 3762 80 (Homo + Spe) 35 AIP, RPF
amg/dL in serum. bIU/mL. cShown in Fig. 1
ANA: anti-nuclear antibody; gl: gland; Homo: homogeneous; IN: interstitial nephritis
RPF: retroperitoneal fibrosis; Spe: speckleda fluorescence microscope. Instead of using anti-total
human IgG antibody as the second antibody, we used
anti-IgG1 (ab50473, Abcam), anti-IgG2 (10122, Alpha
Diagnostic Intl.), anti-IgG3 (10123, Alpha Diagnostic
Intl.), or anti-IgG4 antibodies (ab99821, Abcam). To de-
tect total-IgG ANA, patients’ sera are usually diluted by
the ratios starting from 1:40. To detect each IgG-subclass
ANA, the sera were not diluted because of relatively low
affinities of the second antibodies against subclasses.Results
ANA positivity of IgG4-RD
Of 19 cases that definitely satisfied the 2011 Compre-
hensive Diagnostic Criteria for IgG4-RD by MHLW,
Japan (Table 1), 14 (74 %) were older than 60 years, and
14 (74 %) were male. Lymph node swellings and retro-
peritoneal fibrosis were major manifestations. Eleven pa-
tients (58 %) were ANA-positive at a cut-off titer of 1:40
(range: 1:40–1:320). The ANA patterns were homoge-
neous + speckled or speckled in most cases. Although 7
(37 %) were positive for rheumatoid factor and 2 (11 %)
were positive for anti-SS-A/Ro antibodies, we confirmed
these 9 cases did not fulfill the criteria for rheumatoid
arthritis (RA) or SS. No patients were positive for anti-
DNA, Sm, or U1-RNP antibodies.D cases
ifestations Biopsy source, IgG4+/IgG+ cell ratio
sease, Prostatitis, LN Prostate, 0.60
sease, RPF Submandibular gl, 0.40
or, IP, IN, RPF, LN Submandibular gl, 0.73
l pseudotumor Kidney, 0.70
IP, IN, RPF, LN Submandibular gl, 0.43
tumor Retroorbital tumor, 0.48
or Submandibular gl, 0.57
or, LN Submandibular gl, 0.40
sease Lachrymal gl, 0.41
sease Lachrymal gl, 0.50
Retroperitoneal tumor, 0.70
Pancreas, 0.43
r, Lung nodule, LN Orbital tumor, 0.59
Laryngeal tumor, LN Parotid gl, 0.60 Cervical LN, 0.69
sease, LN Submandibular LN, 0.80
sease, IP, IN, Renal pseudotumor, LN Minor salivary gl, 0.65
r, RPF, Lung nodule, LN Cervical LN, 0.90
Submandibular gl, 0.48
Vater’s ampulla, 0.48
; IP: interstitial pneumonitis; LN: lymph node; RF: rheumatoid factor;
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We selected 5 IgG4-RD patients robustly ANA-positive
with a cut-off titer of 1:80, and examined the IgG sub-
classes of their ANA. Subclass-based ANA test showed
IgG2+ ANA and scant IgG1+ ANA. However, we found no
IgG4+ or IgG3+ ANA (Fig. 1, 2). We confirmed that the
second antibody against IgG4 worked, using direct im-
munofluorescence on a lymph node specimen (IgG4+/IgG+
plasma cell ratio = 0.69) of an IgG4-RD patient (Fig. 1,
lower right panel).
IgG subclasses of ANA in systemic autoimmune diseases
We examined IgG subclasses of ANA in systemic auto-
immune diseases such as SLE, SSc, SS, and PM (Table 2).
The ANA titers ranged from 1:40 to 1:5120 with various
patterns. The Subclass-based ANA test detected IgG1+,
IgG2+, or IgG3+ ANA in the systemic autoimmune
disease cases (Fig. 2, 3). Especially, all cases were IgG2+.
However, IgG4 was not detected (Fig. 2, 3), except in a
patient with SS who showed IgG4-type ANA with per-
ipheral pattern (Fig. 4).
An exceptional case with IgG4-type ANA
A 79-year-old male with SS showed IgG4-type ANA
with peripheral pattern (Fig. 4). Lip biopsy results were
compatible with SS, although anti-IgG4 staining was not
performed. Anti-SS-A/Ro antibody was positive. We saw
no swelling of lacrimal glands, salivary glands, or lymph
nodes. This patient did not meet the criteria for IgG4-
RD and was not considered to have clinical IgG4-RD.
Difference of ANA patterns among IgG subclasses
In serum from one patient, ANA patterns differed
among IgG subclass. Such phenomenon was seen in
Fig. 3 and 4.Fig. 1 Subclass-based ANA test in IgG4-RD, showing immunofluorescence
right panel: We confirmed the second antibody’s function by direct immun
ratio = 0.69) from an IgG4-RD patient (IgG4-RD #14). Bar = 20 μmDiscussion
In IgG4-RD patients, we found no IgG4+ ANA, but did
detect IgG1+ and IgG2+ ANA (Fig. 1 and 2). We also
found IgG4+ ANA was very rare, whereas IgG1/2/3+
ANA were detected in systemic autoimmune diseases
(Fig. 2 and 3). Autoantibodies with cytoplasmic pat-
terns in the Fluoro-HepANA™ test are not exact ANA;
“anti-cytoplasmic” antibodies—e.g., anti-SS-A/Ro, anti-
aminoacyl-tRNA synthetase, and anti-signal recogni-
tion particle antibodies—are known in SS and PM.
Subclass-based ANA tests found IgG1/2/3+ anti-
cytoplasmic antibodies, but not IgG4 (Fig. 2, 3).
IgG4+ ANA is very rare in systemic autoimmune dis-
eases, possibly because serum IgG4/IgG ratios are low,
less than 5 %, in these diseases (Table 2). However, IgG4+
ANA was not detected despite high serum IgG4/IgG ra-
tios (43 %) in IgG4-RD. This implies that IgG4 itself is not
used to make ANA.
Several studies have investigated ANA subclasses in
systemic autoimmune diseases. Zouali et al. reported
that in SLE and mixed connective tissue disease, anti-
double-stranded DNA (dsDNA) antibody was IgG1/3-
dominant, and anti-RNP was IgG2-dominant [11]. Anti-
Sm, anti-RNP, and anti-dsDNA in SLE [12], anti-SS-A/
Ro and anti-SS-B/La in SS [13], and anti-Scl-70 in SSc
[14] are reportedly IgG1-dominant. However, IgG4-type
ANA was hardly detected in all the above reports. Rigo-
poulou et al. examined primary biliary cirrhosis cases,
and found that ANA was IgG1/3-dominant but IgG4
was not detected by subclass-based IIF [15]. The reason
IgG2-type ANA was remarkably frequent in our study
whereas IgG1 and IgG3 were predominant in previous
studies might be that second antibody affinities differed
between studies. In the subclass-based ANA test, titers
cannot be accurately compared between subclasses, asmicroscopy of two typical IgG4-RD cases (IgG4-RD #3 and #5). Lower
ofluorescence of a lymph node specimen (IgG4+/IgG+ plasma cell
Fig. 2 Positivity of each ANA subclass in IgG4-RD and systemic autoimmune diseases. Cyto: positivity of each subclass of anti-cytoplasmic
antibody was also calculated for patients with Sjögren’s syndrome and polymyositis
Table 2 ANA profiles of patients with systemic autoimmune diseases
Case ANA Specific autoantibodies IgG4a IgGa
SLE 1b Spe 320 dsDNA, ssDNA, U1-RNP, Sm 21.3 1830
SLE 2 Homo + Spe 320 dsDNA, ssDNA, SS-A 11 826
SLE 3 Spe 1280 dsDNA, ssDNA, Sm, Ribosome 20 2043
SLE 4 Spe 640 ssDNA, U1-RNP, Sm, SS-A, SS-B 8.3 829
SLE 5 Homo + Spe 1280 dsDNA, ssDNA, U1-RNP, Sm, SS-A, SS-B 7 556
SLE 6 Homo + Spe 160 ssDNA 48.6 1938
SLE 7 Spe 320 dsDNA, SS-A 19.6 1186
SLE 8 Spe 5120 dsDNA, ssDNA, U1-RNP, Sm, SS-A 7 908
SSc 1 Discrete spe 1280 Centromere 7 1177
SSc 2b Discrete spe 1280, Spe 160, Cyto 80 Centromere, SS-A 21.2 1772
SSc 3 Spe 1280 Scl-70, U1-RNP, SS-A 25.5 2147
SSc 4 Discrete spe 1280 Centromere, Scl-70, U1-RNP 12.4 1108
SS 1 Spe 320 SS-A, SS-B 33.4 2974
SS 2 Spe 160 SS-A, SS-B 16.5 1765
SS 3 Spe 80 SS-A, SS-B 74 1370
SS 4c Spe 640 SS-A 228 1721
SS 5 Spe 40, Cyto 80 SS-A 38 2133
SS 6 Spe 160 SS-A, SS-B 14.5 2340
SS 7 Spe 160 SS-A, SS-B 9.5 1882
SS 8b Spe + Nucleolar 80, Cyto 40 SS-A 20.1 1678
PM 1 Spe + Nucleolar 640 Ku 53.5 1668
PM 2b Spe 320, Cyto 40 ssDNA, U1-RNP, Sm, SS-A 12.9 1132
PM 3 Spe 40, Cyto 160 PL-7 15 717
PM 4 Spe 320 U1-RNP, Sm 5 282
PM 5 Spe 1280 Ku, SS-A, SS-B <3 823
PM 6 Spe 40, Cyto 80 SRP 18.4 1365
PM 7 Homo + Spe 160 Not detected 19 2051
amg/dL in serum. bShown in Fig. 3. cShown in Fig. 4
ANA: anti-nuclear antibody; Cyto: cytoplasmic; Discrete spe: discrete speckled; Homo: homogeneous; RNP: ribonucleoprotein; Spe: speckled; SRP: signal
recognition particle
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Fig. 3 Subclass-based ANA test for systemic autoimmune diseases showing immunofluorescence microscopy for each typical case, including
systemic lupus erythematosus (SLE #1), systemic sclerosis (SSc #2), Sjögren’s syndrome (SS #8) and polymyositis (PM #2) showed variation in ANA
patterns among IgG subclasses. In SSc #2, total IgG showed Discrete spe + Speckled + Cyto, while IgG1 showed Discrete spe + Speckled, IgG2
showed Discrete spe + Speckled + Cyto, IgG3 showed Discrete spe + Cyto, and IgG4 showed negative. In SS #8, total IgG showed Speckled +
Nucleolar + Cyto, while IgG1 and IgG2 showed Speckled + Cyto, IgG3 showed Nucleolar + Cyto, and IgG4 showed negative. Bar = 20 μm Discrete
spe: discrete speckled, Cyto: cytoplasmic
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IgG2-type ANA was also detected at moderate levels,
whereas IgG4-type ANA was constantly negative or at
low levels. In our study, IgG4-type ANA was also hardly
detected.
Autoimmune pancreatitis (AIP) is an organ-specific
disorder seen in IgG4-RD. Various autoantibodies, such
as anti-lactoferrin [5] and anti-carbonic anhydrase II [6]
antibodies, are seen in AIP. Asada et al. found anti-
pancreatic secretory trypsin inhibitor (PSTI) antibody in
AIP, and showed that the titers of anti-PSTI antibodyFig. 4 Subclass-based ANA test of a patient with Sjögren’s syndrome (SS #4)
Total IgG showed Speckled, while IgG2 showed Speckled + Cyto, IgG1 and Ig
showed Peripheral. Bar = 20 μm. Cyto: cytoplasmicmoved in parallel with serum IgG4 levels [16]. IgG4
levels change in parallel with IgG4-RD disease activity,
as reported in many studies, including our previous
study [17]. Asada et al. thought that anti-PSTI might be
an important factor in the pathophysiology. However,
immunoblotting of subclasses with anti-IgG1 or anti-
IgG4 as second antibodies showed the subclass was not
IgG4 but IgG1. Possibly, IgG4-type autoantibodies are
difficult to produce in IgG4-RD patients.
However, some autoimmune diseases reportedly show
IgG4-type autoantibodies. Rock et al. reported that IgG4showing IgG4-type ANA. ANA patterns differed among IgG subclasses.
G3 showed Nucleolar + Cyto (with atypical cytoplasmic spots), and IgG4
Kiyama et al. BMC Musculoskeletal Disorders  (2015) 16:129 Page 6 of 8was the most common (100 %) of anti-desmoglein
(Dsg)-1 antibodies detected in sera of patients with
pemphigus foliaceus, and showed the pathogenicity of
IgG4-type anti-Dsg-1 antibody using Balb/c mice [18].
Anti-Dsg-3 antibody in pemphigus vulgaris was also
IgG4-predominant [19]. Beck et al. showed by immuno-
blotting that anti-phospholipase A2 receptor (PLA2R)
antibody in idiopathic membranous nephropathy mainly
consisted of IgG4 [20]. IgG4 is reportedly predominant in
anti-neutrophil cytoplasmic antibody (ANCA). C-ANCA
(IIF), proteinase-3 (PR3)-ANCA (ELISA), and myeloper-
oxidase (MPO)-ANCA (ELISA) in granulomatosis with
polyangiitis (GPA) [21], and MPO-ANCA (ELISA) in
propylthiouracil-induced vasculitis [22] were IgG1/4-
dominant. Others similarly reported that IgG4 made up
most C-ANCA (IIF) and PR3-ANCA (ELISA) in vasculit-
ides [23, 24]. Engelmann et al. reported that anti-cyclic
citrullinated peptide (CCP) antibody was IgG1/4-
dominant in RA [25]. However, IgG4 in vasculitides
and RA might not be pathophysiologically important.
In functional analyses of ANCA, IgG1 and IgG3 PR3-
ANCA can stimulate neutrophils [26], whereas IgG4
PR3-ANCA was only weakly stimulatory to neutro-
phils [27]. In RA patients who had HLA-DR4-shared
epitope, Engelmann et al. found IgG3 anti-CCP antibody
to be predominant, and considered that IgG3-type anti-
body might be more important in the pathophysiology of
RA [28]. As IgG4 has poor ability to activate complements
and antibody-dependent cellular cytotoxicity [29–32],
IgG4 is unlikely to take part in mechanisms of tissue dam-
age in autoimmune diseases.
Interestingly, there seem to be pathogenic and non-
functional IgG4-type autoantibodies. IgG4-type ANCA
is considered less pathogenic, compared to other sub-
class ANCA in ANCA-associated vasculitis [26, 27]. The
affinities between IgG4-type and other subclass ANCA
should be equal, but the abilities of complement activa-
tion are different, so that the role of IgG4-type ANCA
can be less significant than that of other subclass ANCA.
On the other hand, IgG4 anti-PLA2R antibody has highTable 3 Summary of predominant subclasses in autoantibodies in Ig
Diseases Autoantibodies Predominant subclass IgG4 subclass
IgG4-RD ANA IgG2 Negative
IgG4-RD (AIP) Anti-PSTI IgG1 Negative
SLE, SSc, SS, PM ANA IgG1/2/3 Seldom
GPA, Vasculitis ANCA IgG1, IgG4 Frequent
RA ACPA IgG1, IgG4 Frequent
PF, PV Anti-Dsg-1/3 IgG4 Primary
Idiopathic MN Anti-PLA2R IgG4 Primary
ACPA: anti-citrullinated protein antibody; AIP: autoimmune pancreatitis; ANA: anti-n
desmoglein-1 and 3; GPA: granulomatosis with polyangiitis; MN: membranous neph
PSTI: pancreatic secretory trypsin inhibitor; PV: pemphigus vulgaris; RA: rheumatoidaffinity and is considered pathogenic in idiopathic mem-
branous nephropathy [20]. Why IgG4 anti-PLA2R antibody
can exert pathogenicity without ability of complement acti-
vation may be because the pathogenicity is brought by the
destruction of electrical barriers of glomerular basement
membrane.
Taken together, IgG4 usage rates differ among auto-
antibodies and among diseases. IgG4 is associated with
anti-Dsg-1/3, anti-PLA2R, anti-CCP antibodies, and
ANCA, but not with anti-PTSI antibody in AIP or ANA
in IgG4-RD and systemic autoimmune diseases (Table 3).
This asymmetry implies that IgG4 has unknown but cer-
tain physiological or pathological functions. Further ana-
lyses are needed to know its role.
In the present study, we observed ANA patterns dif-
fered among IgG subclasses in some cases (Fig. 3, 4).
When a case has several autoantibodies, the utilized sub-
classes differ by autoantigens. This can be explained by
the hypothesis that each IgG subclass prefers to cover its
own spectrum of antigens. The reason we hardly found
IgG4 in ANA might be that IgG4 does not cover anti-
gens that can be detected by the ANA test—i.e., nuclear
antigens or related microbial antigens. Selective IgG2
subclass deficiency is often associated with bacterial in-
fection by Neisseria meningitidis and Streptococcus pneu-
moniae [33, 34], so that IgG2 is considered to have a
role in protection from these bacteria. The role of IgG4
has not been sufficiently understood. If IgG4 is related
to some microorganism type, and if the microorganism
antigens and autoantigens are similar, as with Dsg-1/3,
PLA2R, PR3, and citrullinated proteins, it would explain
why IgG4-type antibody against those proteins was dom-
inantly generated.
Our results imply that IgG4-RD is not an autoimmune
disease, and that high levels of serum IgG4 in IgG4-RD
are only nonspecific. Subclass-based ANA tests in this
study covered both nuclear and cytoplasmic antigens in
HEp-2 cells, and can screen a wide range of unmodified
ubiquitous antigens. However, this analysis has limita-




Present study, Zouali [11], Eisenberg [12], Maran [13], Vazquez-abad [14]
Brouwer [21], Mellbye [23], Liu [24], Gao [22]
Engelmann [25]
Rock [18], Ding [19]
Beck [20]
uclear antibody; ANCA: anti-neutrophil cytoplasmic antibody; Dsg-1/3:
ropathy; PF: pemphigus foliaceus; PLA2R: phospholipase A2 receptor;
arthritis
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cases is limited in this study. There remains a possibility
that unknown IgG4-type autoantibodies might be found
in IgG4-RD. A further analysis is needed.
Conclusions
We found ANA in IgG4-RD patients are not IgG4-based
despite high serum IgG4 levels. IgG4 was also hardly
found in ANA in systemic autoimmune diseases. We
also observed several patients in whom ANA patterns
differed among IgG subclasses, probably due to differ-
ence in corresponding autoantigens. These findings
imply that each IgG subclass tends to cover its own
spectrum of antigens, and IgG4 is not apparently used
to make ANA.
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